All In Biotech

Drug Trial Radar · NCT04523272

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 528 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

528

Actual

Start

Aug 25, 2020

Primary completion

Jun 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.

Conditions

  • Advanced Renal Cancer

Interventions

  • TQB2450Drug

    TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • AnlotinibDrug

    A multi-target receptor tyrosine kinase inhibitor.

  • SunitinibDrug

    A multi-target receptor tyrosine kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) evaluated by Independent Review Committee(IRC)Time frame: up to 60 weeks

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Sun Yat-sen of Cancer Center

    Guangzhou, Guangdong, China

  • The Affiliated Tumor Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Tenth People's Hospital of Tongji University

    Shanghai, Shanghai Municipality, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

  • The Second Affiliated Hospital of Xi 'an Jiaotong University

    Xi’an, Shanxi, China

  • The First Affiliated Hospital of PLA Air Force Military Medical University

    Xi’an, Shanxi, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China

  • First Affiliated Hospital,School of Medicine,Shihezi University

    Shihezi, Xinjiang, China

  • The Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • Cancer Hospital of The University of Chinese Academy of Sciences

    Hangzhou, Zhejiang, China

  • The First Hospital of Jiaxing

    Jiaxing, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.